527 results
Search Results
2. International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products.
- Author
-
Ikonomou, Laertis, Cuende, Natividad, Forte, Miguel, Grilley, Bambi J., Levine, Aaron D., Munsie, Megan, Rasko, John E.J., Turner, Leigh, Bidkhori, Hamid R., Ciccocioppo, Rachele, Grignon, Felix, Srivastava, Alok, Weiss, Daniel J., Zettler, Patricia, and Levine, Bruce L.
- Subjects
- *
GENE therapy , *CELLULAR therapy , *MARKETING , *MORAL development , *PRODUCT safety - Abstract
The field of regenerative medicine, including cellular immunotherapies, is on a remarkable growth trajectory. Dozens of cell-, tissue- and gene-based products have received marketing authorization worldwide while hundreds-to-thousands are either in preclinical development or under clinical investigation in phased clinical trials. However, the promise of regenerative therapies has also given rise to a global industry of direct-to-consumer offerings of prematurely commercialized cell and cell-based products with unknown safety and efficacy profiles. Since its inception, the International Society for Cell & Gene Therapy Committee on the Ethics of Cell and Gene Therapy has opposed the premature commercialization of unproven cell- and gene-based interventions and supported the development of evidence-based advanced therapy products. In the present Guide, targeted at International Society for Cell & Gene Therapy members, we analyze this industry, focusing in particular on distinctive features of unproven cell and cell-based products and the use of tokens of scientific legitimacy as persuasive marketing devices. We also provide an overview of reporting mechanisms for patients who believe they have been harmed by administration of unapproved and unproven products and suggest practical strategies to address the direct-to-consumer marketing of such products. Development of this Guide epitomizes our continued support for the ethical and rigorous development of cell and cell-based products with patient safety and therapeutic benefit as guiding principles. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Considerations for immune effector cell therapy collections: a white paper from the American Society for Apheresis.
- Author
-
Liu, Hien D., Su, Leon, Winters, Jeffrey L., Thibodeaux, Suzanne R., Park, Yara A., Wu, YanYun, Schwartz, Joseph, Zubair, Abba C., Schneiderman, Jennifer, Gupta, Gaurav K., Ramakrishnan, Sharanya, and Aqui, Nicole A.
- Subjects
- *
CELLULAR therapy , *MANUFACTURING cells , *CHILD patients , *LEUKAPHERESIS , *GENE therapy , *COLLECTIONS - Abstract
This white paper was developed to provide leukapheresis guidance for the collection of mononuclear cells from adult and pediatric patients who are destined for immune effector cell (IEC) therapies for commercial and research applications. Currently, there is considerable variability in leukapheresis processes and limited published information regarding best practices relevant to new cellular therapies, especially IECs. Herein the authors address critical leukapheresis questions in five domains to help guide consistent collection processes and ensure high-quality products. The first four domains are onboarding, pre-collection, collection and post-collection, with protocol feasibility, preparation, care and follow-up of the patient/donor at each step, respectively, and technical considerations during collection. The fifth domain of quality assurance focuses on ensuring product potency, purity, safety and auditing. The American Society for Apheresis (ASFA) Clinical Applications Committee (IEC Therapy Subcommittee) was charged by the society's board of directors with working collaboratively with other ASFA committees and organizations, including the Foundation for the Accreditation of Cellular Therapy, Association for the Advancement of Blood and Biotherapies, American Society for Transplantation and Cellular Therapy, National Marrow Donor Program and International Society for Cell & Gene Therapy, to develop guidelines regarding leukapheresis collection of cells destined for the manufacture of IEC therapies. After a review of the literature and discussion with members of the involved committees and various institutions, a draft guidance was created and circulated for comment and revision. Critical aspects of apheresis that could affect the quality and quantity of the leukapheresis product were identified. These areas were then discussed and reviewed. After consensus, the best practice guidelines were proposed and accepted. In the current era of rapid growth of IEC therapies, it is important to address critical leukapheresis steps to provide high-quality products and more consistent practices and to eliminate redundant efforts. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)
- Author
-
de Boer, Rudolf A., Heymans, Stephane, Backs, Johannes, Carrier, Lucie, Coats, Andrew J.S., Dimmeler, Stefanie, Eschenhagen, Thomas, Filippatos, Gerasimos, Gepstein, Lior, Hulot, Jean‐Sebastien, Knöll, Ralph, Kupatt, Christian, Linke, Wolfgang A., Seidman, Christine E., Tocchetti, C. Gabriele, van der Velden, Jolanda, Walsh, Roddy, Seferovic, Petar M., and Thum, Thomas
- Abstract
Genetic cardiomyopathies are disorders of the cardiac muscle, most often explained by pathogenic mutations in genes encoding sarcomere, cytoskeleton, or ion channel proteins. Clinical phenotypes such as heart failure and arrhythmia are classically treated with generic drugs, but aetiology‐specific and targeted treatments are lacking. As a result, cardiomyopathies still present a major burden to society, and affect many young and older patients. The Translational Committee of the Heart Failure Association (HFA) and the Working Group of Myocardial Function of the European Society of Cardiology (ESC) organized a workshop to discuss recent advances in molecular and physiological studies of various forms of cardiomyopathies. The study of cardiomyopathies has intensified after several new study setups became available, such as induced pluripotent stem cells, three‐dimensional printing of cells, use of scaffolds and engineered heart tissue, with convincing human validation studies. Furthermore, our knowledge on the consequences of mutated proteins has deepened, with relevance for cellular homeostasis, protein quality control and toxicity, often specific to particular cardiomyopathies, with precise effects explaining the aberrations. This has opened up new avenues to treat cardiomyopathies, using contemporary techniques from the molecular toolbox, such as gene editing and repair using CRISPR‐Cas9 techniques, antisense therapies, novel designer drugs, and RNA therapies. In this article, we discuss the connection between biology and diverse clinical presentation, as well as promising new medications and therapeutic avenues, which may be instrumental to come to precision medicine of genetic cardiomyopathies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)
- Author
-
de Boer, Rudolf A., Heymans, Stephane, Backs, Johannes, Carrier, Lucie, Coats, Andrew J. S., Dimmeler, Stefanie, Eschenhagen, Thomas, Filippatos, Gerasimos, Gepstein, Lior, Hulot, Jean-Sebastien, Knöll, Ralph, Kupatt, Christian, Linke, Wolfgang A., Seidman, Christine E., Tocchetti, C. Gabriele, van der Velden, Jolanda, Walsh, Roddy, Seferovic, Petar M., and Thum, Thomas
- Subjects
- *
HOMEOSTASIS , *X-linked genetic disorders , *CARDIAC hypertrophy , *TREATMENT effectiveness , *GENETIC engineering , *GENE therapy , *ARRHYTHMIA , *HEART failure , *MEDICAL societies , *PHENOTYPES - Abstract
Genetic cardiomyopathies are disorders of the cardiac muscle, most often explained by pathogenic mutations in genes encoding sarcomere, cytoskeleton, or ion channel proteins. Clinical phenotypes such as heart failure and arrhythmia are classically treated with generic drugs, but aetiology-specific and targeted treatments are lacking. As a result, cardiomyopathies still present a major burden to society, and affect many young and older patients. The Translational Committee of the Heart Failure Association (HFA) and the Working Group of Myocardial Function of the European Society of Cardiology (ESC) organized a workshop to discuss recent advances in molecular and physiological studies of various forms of cardiomyopathies. The study of cardiomyopathies has intensified after several new study setups became available, such as induced pluripotent stem cells, three-dimensional printing of cells, use of scaffolds and engineered heart tissue, with convincing human validation studies. Furthermore, our knowledge on the consequences of mutated proteins has deepened, with relevance for cellular homeostasis, protein quality control and toxicity, often specific to particular cardiomyopathies, with precise effects explaining the aberrations. This has opened up new avenues to treat cardiomyopathies, using contemporary techniques from the molecular toolbox, such as gene editing and repair using CRISPR-Cas9 techniques, antisense therapies, novel designer drugs, and RNA therapies. In this article, we discuss the connection between biology and diverse clinical presentation, as well as promising new medications and therapeutic avenues, which may be instrumental to come to precision medicine of genetic cardiomyopathies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Handlungsempfehlungen zur Gentherapie der spinalen Muskelatrophie mit Onasemnogene Abeparvovec – AVXS-101: Konsensuspapier der deutschen Vertretung der Gesellschaft für Neuropädiatrie (GNP) und der deutschen Behandlungszentren unter Mitwirkung des Medizinisch-Wissenschaftlichen Beirates der Deutschen Gesellschaft für Muskelkranke (DGM) e. V
- Author
-
Ziegler, Andreas, Wilichowski, Ekkehard, Schara, Ulrike, Hahn, Andreas, Müller-Felber, Wolfgang, Johannsen, Jessika, von der Hagen, Maja, von Moers, Arpad, Stoltenburg, Corinna, Saffari, Afshin, Walter, Maggie C., Husain, Ralf A., Pechmann, Astrid, Köhler, Cornelia, Horber, Veronka, Schwartz, Oliver, and Kirschner, Janbernd
- Abstract
Background: Spinal muscular atrophy (SMA) is a severe, life-limiting neurodegenerative disease. A disease-modifying and approved therapy with nusinersen has been available in Germany since July 2017. Gene therapies offer another promising treatment option through a once in a lifetime administration. In May 2019 a gene replacement therapy for the treatment of SMA was approved for the first time by the U.S. Food and Drug Administration (FDA). An application for approval in Europe has been submitted and is currently pending. Objective: This consensus paper was compiled at the invitation of the German Society for Muscular Diseases (DGM) with the participation of all potential German neuromuscular treatment centers, the German section of the Society for Pediatric Neurology (GNP) and with the involvement of the medical scientific advisory board of the DGM. The aim was to define and establish the necessary prerequisites for a safe and successful application of the new gene replacement therapy in clinical practice. Conclusion: Gene replacement therapy with onasemnogene abeparvovec has the potential to significantly influence the course of SMA. Long-term data on sustainability of effects and possible adverse effects of gene replacement therapy are not yet available. The application of this innovative therapy must be carried out in specialized and appropriately qualified treatment centers under strict safety conditions. This article makes suggestions for the necessary framework conditions and gives recommendations for a systematic pretreatment and posttreatment assessment schedule under gene therapy. The effectiveness and safety of the therapy should be systematically documented in an industry-independent and disease-specific register. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Insights into therapeutic products, preclinical research models, and clinical trials in cardiac regenerative and reparative medicine: where are we now and the way ahead. Current opinion paper of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine
- Author
-
Grigorian-Shamagian, Lilian, Sanz-Ruiz, Ricardo, Climent, Andreu, Badimon, Lina, Barile, Lucio, Bolli, Roberto, Chamuleau, Steven, Grobbee, Diederick E, Janssens, Stefan, Kastrup, Jens, Kragten-Tabatabaie, Leyla, Madonna, Rosalinda, Mathur, Anthony, Menasché, Philippe, Pompilio, Giulio, Prosper, Felipe, Sena, Emily, Smart, Nicola, Zimmermann, Wolfgram-Hubertus, and Fernández-Avilés, Francisco
- Subjects
- *
REGENERATIVE medicine , *MEDICAL research , *CLINICAL trials , *ANIMAL models in research , *MEDICAL personnel - Abstract
Great expectations have been set around the clinical potential of regenerative and reparative medicine in the treatment of cardiovascular diseases [i.e. in particular, heart failure (HF)]. Initial excitement, spurred by encouraging preclinical data, resulted in a rapid translation into clinical research. The sobering outcome of the resulting clinical trials suggests that preclinical testing may have been insufficient to predict clinical outcome. A number of barriers for clinical translation include the inherent variability of the biological products and difficulties to develop potency and quality assays, insufficient rigour of the preclinical research and reproducibility of the results, manufacturing challenges, and scientific irregularities reported in the last years. The failure to achieve clinical success led to an increased scrutiny and scepticism as to the clinical readiness of stem cells and gene therapy products among clinicians, industry stakeholders, and funding bodies. The present impasse has attracted the attention of some of the most active research groups in the field, which were then summoned to analyse the position of the field and tasked to develop a strategy, to re-visit the undoubtedly promising future of cardiovascular regenerative and reparative medicine, based on lessons learned over the past two decades. During the scientific retreat of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine (CARE) in November 2018, the most relevant and timely research aspects in regenerative and/or reparative medicine were presented and critically discussed, with the aim to lay out a strategy for the future development of the field. We report herein the main ideas and conclusions of that meeting. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. WFH State‐of‐the‐art paper 2020: In vivo lentiviral vector gene therapy for haemophilia.
- Author
-
Cantore, Alessio and Naldini, Luigi
- Subjects
- *
GENE therapy , *HEMOPHILIA , *DRUG efficacy , *TRANSGENE expression , *BLOOD coagulation factors - Abstract
Over the last decade, the development of new treatments for haemophilia has progressed at a very rapid pace. Despite all the promising advances in protein products, the prospect offered by gene therapy of a single potentially lifelong treatment remains attractive for people with haemophilia. Transfer to the liver of coagulation factor VIII (FVIII) or factor IX (FIX) transgenes has indeed the potential to stably restore the dysfunctional coagulation process. Recombinant adeno‐associated virus (AAV)‐derived vectors are widely employed for liver‐directed gene therapy, given their very good efficacy and safety profile, shown in several preclinical and clinical studies. However, there are some limitations associated with AAV vectors, such as their predominantly episomal nature in the nucleus of target cells and the widespread pre‐existing immunity against the parental virus in humans. By contrast, HIV‐derived lentiviral vectors (LV) integrate into the target cell chromatin and are maintained as the cells duplicate their genome, a potential advantage for establishing long‐term expression especially in paediatric patients, in which the liver undergoes substantial growth. Systemic administration of LV allowed stable multi‐year transgene expression in the liver of mice and dogs. More recently, improved phagocytosis‐shielded LV were generated, which, following intravenous administration to non‐human primates, showed selective targeting of liver and spleen and enhanced hepatocyte gene transfer, achieving up to supra‐normal activity of both human FVIII and FIX transgenes. These studies support further preclinical assessment and clinical evaluation of in vivo liver‐directed LV gene therapy for haemophilia. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. CRISPR-M: Predicting sgRNA off-target effect using a multi-view deep learning network.
- Author
-
Sun, Jialiang, Guo, Jun, and Liu, Jian
- Subjects
- *
DEEP learning , *RECURRENT neural networks , *CONVOLUTIONAL neural networks , *GENOME editing , *GENE therapy , *AGRICULTURAL productivity , *CRISPRS - Abstract
Using the CRISPR-Cas9 system to perform base substitutions at the target site is a typical technique for genome editing with the potential for applications in gene therapy and agricultural productivity. When the CRISPR-Cas9 system uses guide RNA to direct the Cas9 endonuclease to the target site, it may misdirect it to a potential off-target site, resulting in an unintended genome editing. Although several computational methods have been proposed to predict off-target effects, there is still room for improvement in the off-target effect prediction capability. In this paper, we present an effective approach called CRISPR-M with a new encoding scheme and a novel multi-view deep learning model to predict the sgRNA off-target effects for target sites containing indels and mismatches. CRISPR-M takes advantage of convolutional neural networks and bidirectional long short-term memory recurrent neural networks to construct a three-branch network towards multi-views. Compared with existing methods, CRISPR-M demonstrates significant performance advantages running on real-world datasets. Furthermore, experimental analysis of CRISPR-M under multiple metrics reveals its capability to extract features and validates its superiority on sgRNA off-target effect predictions. Author summary: Genome editing using the CRISPR-Cas9 system, particularly base substitutions directed by guide RNA, holds immense potential for applications in gene therapy and agricultural productivity. However, the risk of unintended off-target effects poses a challenge, as misdirection of the Cas9 endonuclease can lead to unintended genome alterations. While computational methods exist for predicting off-target effects, there remains a need for encoding methods with more representation space and deep learning models with generalization capability and the adaptability. This paper introduces CRISPR-M, an innovative approach addressing the limitations of existing methods in predicting off-target effects, especially for target sites with indels and mismatches. CRISPR-M employs a novel encoding scheme and a multi-view deep learning model, combining convolutional neural networks and bidirectional long short-term memory recurrent neural networks. The three-branch network structure enhances the prediction accuracy by considering multiple perspectives. Compared with previous representative methods, CRISPR-M exhibits remarkable performance advantages when applied to real-world datasets. The experimental evaluation of CRISPR-M, assessed by various metrics such as ROC, PRC, GC content and melting temperature, demonstrates its ability to extract meaningful features and establishes its superiority in predicting off-target effects of sgRNA. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. New Perspectives of Therapies in Osteogenesis Imperfecta—A Literature Review.
- Author
-
Dinulescu, Alexandru, Păsărică, Alexandru-Sorin, Carp, Mădălina, Dușcă, Andrei, Dijmărescu, Irina, Pavelescu, Mirela Luminița, Păcurar, Daniela, and Ulici, Alexandru
- Subjects
- *
LITERATURE reviews , *OSTEOGENESIS imperfecta , *BONE density , *SKELETAL dysplasia , *BONE growth , *BONE fractures - Abstract
(1) Background: Osteogenesis imperfecta (OI) is a rare skeletal dysplasia characterized as a heterogeneous disorder group with well-defined phenotypic and genetic features that share uncommon bone fragility. The current treatment options, medical and orthopedic, are limited and not efficient enough to improve the low bone density, bone fragility, growth, and mobility of the affected individuals, creating the need for alternative therapeutic agents. (2) Methods: We searched the medical database to find papers regarding treatments for OI other than conventional ones. We included 45 publications. (3) Results: In reviewing the literature, eight new potential therapies for OI were identified, proving promising results in cells and animal models or in human practice, but further research is still needed. Bone marrow transplantation is a promising therapy in mice, adults, and children, decreasing the fracture rate with a beneficial effect on structural bone proprieties. Anti-RANKL antibodies generated controversial results related to the therapy schedule, from no change in the fracture rate to improvement in the bone mineral density resorption markers and bone formation, but with adverse effects related to hypercalcemia. Sclerostin inhibitors in murine models demonstrated an increase in the bone formation rate and trabecular cortical bone mass, and a few human studies showed an increase in biomarkers and BMD and the downregulation of resorption markers. Recombinant human parathormone and TGF-β generated good results in human studies by increasing BMD, depending on the type of OI. Gene therapy, 4-phenylbutiric acid, and inhibition of eIF2α phosphatase enzymes have only been studied in cell cultures and animal models, with promising results. (4) Conclusions: This paper focuses on eight potential therapies for OI, but there is not yet enough data for a new, generally accepted treatment. Most of them showed promising results, but further research is needed, especially in the pediatric field. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. The enigma of sickle cell hepatopathy: Pathophysiology, clinical manifestations and therapy.
- Author
-
Rizvi, Insia, Solipuram, Divya, Kaur, Navneet, Komel, Aqsa, Batool, Saba, and Wang, Jennifer
- Abstract
Summary Sickle cell disease (SCD) is one of the most common genetic disorders in the world predominantly affecting economically disadvantaged populations. There is a notable discrepancy between the growing adult SCD population and available diagnostic and therapeutic interventions for SCD. Sickle cell hepatopathy (SCH) is an all‐inclusive term to describe the acute and chronic liver manifestations of SCD. The pathophysiology of SCH follows no defined pattern or sequence that poses challenges to clinicians and researchers alike. Evidence is lacking for this underreported disease at various levels from diagnostic to therapeutic options. This paper reviews the basic pathophysiology, clinical features, biochemical and radiological findings of various SCH manifestations and outlines the management of each condition. Old and new therapy options in SCD including hydroxyurea, red blood cell exchange transfusion, ursodeoxycholic acid, voxelotor, l‐glutamine and crizanlizumab have been reviewed to investigate the role of these options in treating SCH. The role of liver transplant, haematopoietic stem cell transplant and gene therapy in SCH patients have been reviewed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. State‐of‐the‐art therapies for fragile X syndrome.
- Author
-
Protic, Dragana and Hagerman, Randi
- Subjects
- *
FRAGILE X syndrome , *SLEEP , *AUTISM spectrum disorders , *LANGUAGE delay , *GENE therapy - Abstract
Fragile X syndrome (FXS) is a neurodevelopmental disorder caused by a full mutation (> 200 CGG repeats) in the FMR1 gene. FXS is the leading cause of inherited intellectual disabilities and the most commonly known genetic cause of autism spectrum disorder. Children with FXS experience behavioral and sleep problems, anxiety, inattention, learning difficulties, and speech and language delays. There are no approved medications for FXS; however, there are several interventions and treatments aimed at managing the symptoms and improving the quality of life of individuals with FXS. A combination of non‐pharmacological therapies and pharmacotherapy is currently the most effective treatment for FXS. Currently, several targeted treatments, such as metformin, sertraline, and cannabidiol, can be used by clinicians to treat FXS. Gene therapy is rapidly developing and holds potential as a prospective treatment option. Soon its efficacy and safety in patients with FXS will be demonstrated. What this paper adds: Targeted treatment of fragile X syndrome (FXS) is the best current therapeutic approach.Gene therapy holds potential as a prospective treatment for FXS in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Advanced gene nanocarriers/scaffolds in nonviral-mediated delivery system for tissue regeneration and repair.
- Author
-
Zhang, Wanheng, Hou, Yan, Yin, Shiyi, Miao, Qi, Lee, Kyubae, Zhou, Xiaojian, and Wang, Yongtao
- Subjects
- *
BONE regeneration , *REGENERATION (Biology) , *NANOCARRIERS , *GENE therapy , *ARTICULAR cartilage , *CARTILAGE , *BLOOD vessels - Abstract
Tissue regeneration technology has been rapidly developed and widely applied in tissue engineering and repair. Compared with traditional approaches like surgical treatment, the rising gene therapy is able to have a durable effect on tissue regeneration, such as impaired bone regeneration, articular cartilage repair and cancer-resected tissue repair. Gene therapy can also facilitate the production of in situ therapeutic factors, thus minimizing the diffusion or loss of gene complexes and enabling spatiotemporally controlled release of gene products for tissue regeneration. Among different gene delivery vectors and supportive gene-activated matrices, advanced gene/drug nanocarriers attract exceptional attraction due to their tunable physiochemical properties, as well as excellent adaptive performance in gene therapy for tissue regeneration, such as bone, cartilage, blood vessel, nerve and cancer-resected tissue repair. This paper reviews the recent advances on nonviral-mediated gene delivery systems with an emphasis on the important role of advanced nanocarriers in gene therapy and tissue regeneration. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. To Dilute or Not to Dilute: Nominal Titer Dosing for Genetic Medicines.
- Author
-
Faya, Paul and Zhang, Tianhui
- Abstract
ABSTRACT Recombinant adeno‐associated virus (AAV) has become a popular platform for many gene therapy applications. The strength of AAV‐based products is a critical quality attribute that affects the efficacy of the drug and is measured as the concentration of vector genomes, or physical titer. Because the dosing of patients is based on the titer measurement, it is critical for manufacturers to ensure that the measured titer of the drug product is close to the actual concentration of the batch. Historically, dosing calculations have been performed using the measured titer, which is reported on the drug product label. However, due to recent regulatory guidance, sponsors are now expected to label the drug product with nominal or “target” titer. This new expectation for gene therapy products can pose a challenge in the presence of process and analytical variability. In particular, the manufacturer must decide if a dilution of the drug substance is warranted at the drug product stage to bring the strength in line with the nominal value. In this paper, we present two straightforward statistical methods to aid the manufacturer in the dilution decision. These approaches use the understanding of process and analytical variability to compute probabilities of achieving the desired drug product titer. We also provide an approach for determining an optimal assay replication strategy for achieving the desired probability of meeting drug product release specifications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Recent progress of iron-based nanomaterials in gene delivery and tumor gene therapy.
- Author
-
Gong, Ya, Hu, Xiaoyan, Chen, Ming, and Wang, Jun
- Subjects
- *
GENE therapy , *NANOSTRUCTURED materials , *MAGNETIC resonance imaging , *GENETIC vectors , *GENE expression , *INSERTION mutation - Abstract
Gene therapy aims to modify or manipulate gene expression and change the biological characteristics of living cells to achieve the purpose of treating diseases. The safe, efficient, and stable expression of exogenous genes in cells is crucial for the success of gene therapy, which is closely related to the vectors used in gene therapy. Currently, gene therapy vectors are mainly divided into two categories: viral vectors and non-viral vectors. Viral vectors are widely used due to the advantages of persistent and stable expression, high transfection efficiency, but they also have certain issues such as infectivity, high immunological rejection, randomness of insertion mutation, carcinogenicity, and limited vector capacity. Non-viral vectors have the advantages of non-infectivity, controllable chemical structure, and unlimited vector capacity, but the transfection efficiency is low. With the rapid development of nanotechnology, the unique physicochemical properties of nanomaterials have attracted increasing attention in the field of drug and gene delivery. Among many nanomaterials, iron-based nanomaterials have attracted much attention due to their superior physicochemical properties, such as Fenton reaction, magnetic resonance imaging, magnetothermal therapy, photothermal therapy, gene delivery, magnetically-assisted drug delivery, cell and tissue targeting, and so on. In this paper, the research progress of iron-based nanomaterials in gene delivery and tumor gene therapy is reviewed, and the future application direction of iron-based nanomaterials is further prospected. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Filling the gap: the workforce of tomorrow for CGT manufacturing as the sector advances.
- Author
-
Hopewell, Emily, Pike, Nirupama (Rupa), Lembong, Josephine, Hewitt, Matthew, and Fekete, Natalie
- Subjects
- *
LABOR supply , *TECHNOLOGICAL progress , *MANUFACTURING industries , *GENE therapy , *SMALL business , *QUALITY control , *ADVANCED planning & scheduling , *SKILLED labor - Abstract
Workforce education and development are key cornerstones in advancing and maturing the Cell & Gene Therapy sector. A skilled worker shortage can significantly impact and delay progress as well as the quality of output for any developer, thereby negatively impacting a patient's access to life-saving treatments. Several roundtable discussions were held at the International Society for Cell & Gene Therapy (ISCT) 2023 Annual Meeting to dive deeper into the current state of workforce development and solutions to address this bottleneck. One roundtable discussion was co-hosted by the Alliance for Regenerative Medicine (ARM) and ISCT, which focused on the gap analysis provided for the United States Cell & Gene Therapy (CGT) sector, highlighting the lack of skilled workers in manufacturing and quality control. In this manuscript, the roundtable participants continue this conversation, review the roles and staffing requirements in both academic and industry as well as small and large company settings. The adoption of increased manufacturing automation is one promising solution to propel the sector forward. However, automation alone won't replace on-site staff, but will lower the bar to entry for a larger pool of people and require different training. This paper also addresses the workforce development and training paradigm shift as advanced manufacturing techniques are implemented, which will differ considerably based on the type of manufacturing efforts, thus emphasizing the need for a well-thought-out strategy to up-skill and re-skill the technical workforce to adapt to these advancements. Organizations such as ISCT and ARM have a role to play in propelling the field forward, providing awareness and education to stakeholders at all levels, as well as acting as a convener and participating as a key stakeholder in discussions and partnerships between academia and industry towards solutions for training the best personnel for CGT manufacturing. This scope includes novel digital tools and technologies to simplify training to increase access to new talent pools interested in careers in a rapidly advancing sector. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Cardioprotection by gene therapy: A review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology.
- Author
-
Madonna, Rosalinda, Cadeddu, Christian, Deidda, Martino, Giricz, Zoltán, Madeddu, Clelia, Mele, Donato, Monte, Ines, Novo, Giuseppina, Pagliaro, Pasquale, Pepe, Alessia, Spallarossa, Paolo, Tocchetti, Carlo Gabriele, Varga, Zoltán V., Zito, Concetta, Yong-Jian Geng, Mercuro, Giuseppe, and Ferdinandy, Peter
- Subjects
- *
GENE therapy , *TEAMS in the workplace , *CARDIOTOXICITY , *CORONARY heart disease treatment , *TREATMENT of reperfusion injuries , *CELLULAR signal transduction - Abstract
Ischemic heart disease remains the leading cause of death worldwide. Ischemic pre-, post-, and remote conditionings trigger endogenous cardioprotection that renders the heart resistant to ischemic-reperfusion injury (IRI). Mimicking endogenous cardioprotection by modulating genes involved in cardioprotective signal transduction provides an opportunity to reproduce endogenous cardioprotection with better possibilities of translation into the clinical setting. Genes and signaling pathways by which conditioning maneuvers exert their effects on the heart are partially understood. This is due to the targeted approach that allowed identifying one or a few genes associated with IRI and cardioprotection. Genes critical for signaling pathways in cardioprotection include protectomiRs (e.g., microRNA 125b*), ZAC1 transcription factor, pro-inflammatory genes such as cycloxygenase (COX)-2 and inducible nitric oxide synthase (iNOS), antioxidant enzymes such as hemoxygenase (HO)-1, extracellular and manganese superoxidase dismutases (ec-SOD and Mg-SOD), heat shock proteins (HSPs), growth factors such as insulin like growth factor (IGF)-1 and hepatocyte growth factor (HGF), antiapoptotic proteins such as Bcl-2 and Bcl-xL, pro-apoptotic proteins such as FasL, Bcl-2, Bax, caspase-3 and p53, and proangiogenic genes such as TGFbeta, sphingosine kinase 1 (SPK1), and PI3K-Akt. By identifying the gene expression profiles of IRI and ischemic conditioning, one may reveal potential gene targets responsible for cardioprotection. In this manuscript, we review the current state of the art of gene therapy in cardioprotection and propose that gene expression analysis facilitates the identification of individual genes associated with cardioprotection. We discuss signaling pathways associated with cardioprotection that can be targeted by gene therapy to achieve cardioprotection. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. Gene Therapy in Pediatric Orthopedics.
- Author
-
Olaonipekun, Emmanuel, Lisyansky, Anthony, Olaonipekun, Robin, Merabia, Bouchra Ghania, Gaber, Karim, and Kishta, Waleed
- Subjects
- *
PEDIATRIC orthopedics , *GENE therapy , *PEDIATRIC therapy , *SPINAL muscular atrophy , *DUCHENNE muscular dystrophy , *GENETIC vectors , *GENETIC transformation - Abstract
Gene therapy is gaining traction as an effective treatment for several deleterious disorders by delivering genetic material using viral or non-viral vectors to correct mutated genes. Research in the field focuses primarily on the treatment of cancers; however, it shows great promise for treating diseases related to pediatric orthopedics. This review aims to describe gene therapy's application, efficacy and safety in pediatric orthopedics. This paper will examine common pediatric orthopedic disorders including Duchenne muscular dystrophy, osteogenesis imperfecta, spinal muscular atrophy and osteosarcoma. Overall, gene therapy for spinal muscular atrophy and Duchenne muscular dystrophy has made great advances with approved gene therapy drugs already in use, while therapy for osteogenesis imperfecta and osteosarcoma treatments is still widely preclinical but still promising. As a whole, gene therapy is rapidly advancing in the field of pediatric orthopedics; however, further research is crucial in continuing and spreading these advancements and for the treatment of other debilitating pediatric-related orthopedic disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. 铁死亡相关的环状 RNA 在疾病中的作用及机制.
- Author
-
王 芹, 何梦婕, and 龙方懿
- Abstract
Circular RNA (circRNA) is a special class of non-coding RNA (ncRNA) in eukaryotic cells, which is highly stable. At present, circRNA has been widely found to be involved in the occurrence and development of various diseases as microRNA (miRNA) sponges. As a research hotspot in recent years, the function and effects of circRNA are constantly being discovered and utilized. CircRNAs can act as protein scaffolds to bind targets more tightly and regulate transcription of disease signaling molecules, as well as participate in protein expression as translation templates. A substantial body of research has established the pivotal role of ferroptosis in disease development. Iron and lipid metabolism-related targets are recognized as key components in the regulation of ferroptosis. Recent studies have revealed that circRNA not only participates in ferroptosis regulation as a miRNA and protein scaffold but also exerts control over ferroptosis-related signaling molecules at the transcriptional level. Currently, synthetic circRNA molecules have been engineered for the development of RNA vaccines. Additionally, a range of gene therapy technologies and drug delivery vectors offer a promising foundation for the development of therapeutics targeting circRNA. This paper describes the functions and effects of circRNA, its role as a key target in the regulation of ferroptosis, and its implications in various diseases. Special emphasis is placed on discussing the role of circRNA in multisystem diseases, including tumors, nervous system disorders, and diabetes-related complications. Additionally, drug development strategies related to circRNA are summarized to provide insights for the development of therapeutic drugs targeting ferroptosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Advancements in Viral Gene Therapy for Gaucher Disease.
- Author
-
Kulkarni, Akhil, Chen, Tiffany, Sidransky, Ellen, and Han, Tae-Un
- Subjects
- *
GAUCHER'S disease , *GENE therapy , *VIRAL genes , *ENZYME replacement therapy , *LYSOSOMAL storage diseases , *GENETIC vectors , *DYSPLASIA - Abstract
Gaucher disease, an autosomal recessively inherited lysosomal storage disorder, results from biallelic mutations in the GBA1 gene resulting in deficient activity of the enzyme glucocerebrosidase. In Gaucher disease, the reduced levels and activity of glucocerebrosidase lead to a disparity in the rates of formation and breakdown of glucocerebroside and glucosylsphingosine, resulting in the accumulation of these lipid substrates in the lysosome. This gives rise to the development of Gaucher cells, engorged macrophages with a characteristic wrinkled tissue paper appearance. There are both non-neuronopathic (type 1) and neuronopathic (types 2 and 3) forms of Gaucher disease, associated with varying degrees of severity. The visceral and hematologic manifestations of Gaucher disease respond well to both enzyme replacement therapy and substrate reduction therapy. However, these therapies do not improve the neuronopathic manifestations, as they cannot cross the blood–brain barrier. There is now an established precedent for treating lysosomal storage disorders with gene therapy strategies, as many have the potential to cross into the brain. The range of the gene therapies being employed is broad, but this review aimed to discuss the progress, advances, and challenges in developing viral gene therapy as a treatment for Gaucher disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Age-related hearing loss: An updated and comprehensive review of the interventions.
- Author
-
Tavanai, Elham, Rahimi, Vida, Khalili, Mohammad Ehsan, Falahzadeh, Somayeh, Zarandy, Masoud Motasaddi, and Mohammadkhani, Ghassem
- Subjects
- *
HEARING disorders , *AUDITORY pathways , *PRESBYCUSIS , *NOISE-induced deafness , *GENE therapy , *TREATMENT duration , *CELLULAR therapy , *HEARING levels - Abstract
Aging causes progressive degenerative changes in many organs, particularly the auditory system. Several attempts have been conducted to investigate preventive and therapeutic strategy/strategies for age-related auditory dysfunction, such as maintaining a healthy lifestyle through good nutrition, lower anxiety levels, and noise exposure, different pharmacological approaches, gene and cell therapy, and other strategies. However, it is not clear which approach is the best to slow down these dysfunctions because several different underlying mechanistic pathways are associated with presbycusis which eventually leads to different types of this disease. A combination of several methods is probably required, whereas the effectiveness for some people needs to be monitored. The effectiveness of treatments will not be the same for all; therefore, we may need to have a unique and personalized approach to the prevention and treatment of ARHL for each person. In addition, each method needs to specify what type of presbycusis can prevent or treat and provide complete information about the extent, duration of treatment, persistency of treatment, side effects, and whether the approach is for treatment or prevention or even both. This paper reviews the updated literature, which targets current interventions for age-related hearing loss. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors.
- Author
-
Paun, Radu A., Jurchuk, Sarah, and Tabrizian, Maryam
- Subjects
- *
TUMOR treatment , *NANOPARTICLES , *DRUG delivery systems , *CANCER prognosis , *SMALL molecules , *NANOMEDICINE , *POLYMERSOMES - Abstract
Lipid nanoparticles (LNPs) are biocompatible drug delivery systems that have found numerous applications in medicine. Their versatile nature enables the encapsulation and targeting of various types of medically relevant molecular cargo, including oligonucleotides, proteins, and small molecules for the treatment of diseases, such as cancer. Cancers that form solid tumors are particularly relevant for LNP-based therapeutics due to the enhanced permeation and retention effect that allows nanoparticles to accumulate within the tumor tissue. Additionally, LNPs can be formulated for both locoregional and systemic delivery depending on the tumor type and stage. To date, LNPs have been used extensively in the clinic to reduce systemic toxicity and improve outcomes in cancer patients by encapsulating chemotherapeutic drugs. Next-generation lipid nanoparticles are currently being developed to expand their use in gene therapy and immunotherapy, as well as to enable the co-encapsulation of multiple drugs in a single system. Other developments include the design of targeted LNPs to specific cells and tissues, and triggerable release systems to control cargo delivery at the tumor site. This review paper highlights recent developments in LNP drug delivery formulations and focuses on the treatment of solid tumors, while also discussing some of their current translational limitations and potential opportunities in the field. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. 细胞因子治疗骨关节炎的研究现状及应用前景.
- Author
-
张克凡 and 石 辉
- Subjects
- *
STEM cell treatment , *CARTILAGE regeneration , *MESENCHYMAL stem cells , *TRANSFORMING growth factors , *WNT signal transduction , *PLATELET-rich plasma , *INTERLEUKIN-1 receptors - Abstract
BACKGROUND: In cartilage degeneration in osteoarthritis, cytokines and signaling pathways that target chondrocytes play an important role. OBJECTIVE: To review the latest research progress of osteoarthritis related cytokines and signaling pathways in recent years, such as the mechanism of action and treatment modalities, in order to provide a basis for future exploration of new therapeutic targets and modalities. METHODS: Literature search was conducted on CNKI, WanFang, VIP, PubMed, Web of Science, and Medline databases. Chinese search terms were “osteoarthritis, cytokines, signal pathway, chondrocyte, inflammation, treatment”. Finally, 60 papers were included for review. RESULTS AND CONCLUSION: (1) In current studies, it is believed that the specific mechanism of osteoarthritis is not clear, and a large number of studies have shown that osteoarthritis is strongly associated with cytokines and signaling pathways, which is a complex process of action. Relevant studies taking cytokines and signaling pathways as therapeutic breakthroughs are also the current hot spot. (2) The receptor antagonists of pro-inflammatory factors such as interleukin 1 are not effective in the treatment of osteoarthritis, and more studies turn to gene therapy. (3) The therapeutic methods of transforming growth factor β, recombinant factors of Wnt signaling pathway, gene therapy and mesenchymal stem cells have obtained positive research results. However, basic and clinical studies on safety and efficacy are likely to be conducted in future studies. (4) At present, relevant therapeutic methods such as platelet-rich plasma have been widely used in clinical practice, while recombinant factor, gene therapy and mesenchymal stem cell therapy are all in the research stage, among which mesenchymal stem cell therapy and gene therapy are expected to make breakthroughs in the field of cartilage repair and regeneration, and are worthy of expectation in the future. However, more clinical and basic studies are needed to verify its effectiveness and safety, explore its mechanism of action and scope of application, and set standards for its clinical use. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. KLHL40-Related Myopathy: A Systematic Review and Insight into a Follow-up Biomarker via a New Case Report.
- Author
-
Buchignani, Bianca, Marinella, Gemma, Pasquariello, Rosa, Sgherri, Giada, Frosini, Silvia, Santorelli, Filippo Maria, Orsini, Alessandro, Battini, Roberta, and Astrea, Guja
- Subjects
- *
NEMALINE myopathy , *MUSCLE diseases , *NATURAL history , *GENE therapy , *DISEASE progression - Abstract
Background: Mutations in the KLHL40 gene are a common cause of severe or even lethal nemaline myopathy. Some cases with mild forms have been described, although the cases are still anecdotal. The aim of this paper was to systematically review the cases described in the literature and to describe a 12-year clinical and imaging follow-up in an Italian patient with KLHL40- related myopathy in order to suggest possible follow-up measurements. Methods: Having searched through three electronic databases (PubMed, Scopus, and EBSCO), 18 articles describing 65 patients with homozygous or compound heterozygous KLHL40 mutations were selected. A patient with a KLHL40 homozygous mutation (c.1582G>A/p.E528K) was added and clinical and genetic data were collected. Results: The most common mutation identified in our systematic review was the (c.1516A>C) followed by the (c.1582G>A). In our review, 60% percent of the patients died within the first 4 years of life. Clinical features were similar across the sample. Unfortunately, however, there is no record of the natural history data in the surviving patients. The 12-year follow-up of our patient revealed a slow improvement in her clinical course, identifying muscle MRI as the only possible marker of disease progression. Conclusions: Due to its clinical and genotype homogeneity, KLHL40-related myopathy may be a condition that would greatly benefit from the development of new gene therapies; muscle MRI could be a good biomarker to monitor disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Toxicologic Neuropathology of Novel Biotherapeutics.
- Author
-
Bangari, Dinesh S., Lanigan, Lisa G., Cramer, Sarah D., Grieves, Jessica L., Meisner, René, Rogers, Arlin B., Galbreath, Elizabeth J., and Bolon, Brad
- Subjects
- *
NEUROLOGICAL disorders , *CENTRAL nervous system , *GENOME editing , *GENE therapy , *NUCLEIC acids - Abstract
Biotherapeutic modalities such as cell therapies, gene therapies, nucleic acids, and proteins are increasingly investigated as disease-modifying treatments for severe and life-threatening neurodegenerative disorders. Such diverse bio-derived test articles are fraught with unique and often unpredictable biological consequences, while guidance regarding nonclinical experimental design, neuropathology evaluation, and interpretation is often limited. This paper summarizes key messages offered during a half-day continuing education course on toxicologic neuropathology of neuro-targeted biotherapeutics. Topics included fundamental neurobiology concepts, pharmacology, frequent toxicological findings, and their interpretation including adversity decisions. Covered biotherapeutic classes included cell therapies, gene editing and gene therapy vectors, nucleic acids, and proteins. If agents are administered directly into the central nervous system, initial screening using hematoxylin and eosin (H&E)-stained sections of currently recommended neural organs (brain [7 levels], spinal cord [3 levels], and sciatic nerve) may need to expand to include other components (e.g., more brain levels, ganglia, and/or additional nerves) and/or special neurohistological procedures to characterize possible neural effects (e.g., cell type-specific markers for reactive glial cells). Scientists who evaluate the safety of novel biologics will find this paper to be a practical reference for preclinical safety testing and risk assessment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. International Society for Cell and Gene Therapy of Cancer (ISCGT) annual meeting: conference overview and introduction to the symposium papers.
- Author
-
Guinn, Barbara-ann, Norris, James S., LaiQiang Huang, Farzaneh, Farzin, Kasahara, Noriyuki, and Deisseroth, Albert B.
- Subjects
- *
CONFERENCES & conventions , *MEETINGS , *MEDICAL societies , *CELLULAR therapy , *GENE therapy - Abstract
Information about several papers discussed at a symposium on cell and gene therapy of cancer by the International Society for Cell and Gene Therapy of Cancer is presented. The event was organized by Jim Norris, BSB Medical University of South Carolina, and aided by Katherine Lindley, BSB Medical University of South Carolina. The meeting features reports of highly promising cell-based therapies.
- Published
- 2006
- Full Text
- View/download PDF
27. Educational paper.
- Author
-
Sundaram, Venki, Moore, Anthony, Ali, Robin, and Bainbridge, James
- Subjects
- *
RETINAL degeneration , *DEGENERATION (Pathology) , *RETINAL diseases , *GENE therapy , *THERAPEUTICS - Abstract
Retinal dystrophies are inherited disorders of photoreceptor and retinal pigment epithelial function that may result in severe visual impairment. Advances in molecular genetics have helped identify many of the gene defects responsible, and progress in gene transfer technology has enabled therapeutic strategies to be developed and applied. The first human clinical trials of gene therapy for RPE65 associated retinal dystrophy have shown promising initial results and have helped prepare the way for further trials of gene therapy for inherited retinal disorders. The results of these trials will provide further insight into the safety and efficacy of gene therapy for a range of currently untreatable and debilitating eye disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
28. Renal artery injection for delivery of biological materials to the glomerulus (Methods in Renal Research Paper).
- Author
-
TAKABATAKE, YOSHITSUGU, ISAKA, YOSHITAKA, and IMAI, ENYU
- Subjects
- *
SMALL interfering RNA , *RENAL artery , *ELECTROPORATION , *GENES , *KIDNEY glomerulus , *GREEN fluorescent protein , *MICROORGANISMS - Abstract
Aim: We investigated whether injection of synthetic small interfering siRNAs via renal artery followed by electroporation could be effective in silencing specific genes in glomerulus. Methods: Solution of siRNA targeting enhanced green fluorescent protein (EGFP) was injected via the renal artery of EGFP-transgenic rats followed by delivery of electric pulses. Results: The delivery of siRNA reduced endogenous EGFP expression, mainly in glomerular mesangial cells. Conclusion: Electroporation-mediated gene transfer system via renal artery in rats is very useful for the delivery of a range of different materials including cells, viruses and proteins. Here, we provide a step-by-step description of this perfusion method and a discussion of the key points for the success of the technique. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
29. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts1 <FN ID="FN1"><NO>1</NO>This paper was presented at the annual meeting of the Association for Academic Surgery, Boston, MA, November 7–9, 2002.</FN>
- Author
-
Celinski, Scott A., Fisher, William E., Amaya, Felipe, Wu, Yuan Qing, Yao, Q., Youker, Keith A., and Li, Min
- Subjects
- *
PANCREAS , *ADENOCARCINOMA , *SOMATOSTATIN , *CANCER - Abstract
Background.Most human pancreatic adenocarcinoma cells do not express somatostatin receptors, and somatostatin does not inhibit the growth of these cancers. We have demonstrated previously that somatostatin inhibits the growth of pancreatic cancers expressing somatostatin receptor subtype-2 (SSTR2), but not receptor-negative cancers. SSTR2 expression may be an important tumor-suppressor pathway that is lost in human pancreatic cancer. We hypothesized that SSTR2 gene transfer would restore the growth-inhibitory response of human pancreatic cancer to somatostatin.Materials and methods.Palpable human pancreatic adenocarcinoma tumors were established on the backs of nude mice by subcutaneous injection of cultured cells (Panc-1). The animals were divided into 5 groups (n = 10/group). Group I served as an untreated control. Group II received an intramuscular injection of the long-acting somatostatin analogue Sandostatin LAR. Group III received Lac-Z expressing adenovirus via intraperitoneal injection. Group IV received SSTR2 expressing adenovirus via intraperitoneal injection. Group V received SSTR2 expressing adenovirus via intraperitoneal injection and an intramuscular injection of Sandostatin LAR. The rate of tumor growth was assessed with calipers. After 28 days, the animals were anesthetized and exsanguanated, and the tumors were excised and weighed. Plasma somatostatin and octreotide levels were measured by radioimmunoassay. Expression of cell-surface somatostatin-receptor protein and known tumor-suppressor proteins was determined by reverse transcriptase-polymerase chain reaction, Western blot, and immunohistochemistry.Results.Systemic delivery of SSTR2-expressing adenovirus by intraperitoneal injection resulted in expression of SSTR2 protein in the subcutaneous human pancreatic cancers. Final tumor weight was significantly decreased in the groups expressing SSTR2 receptors compared to the other 3 groups. Treatment with Sandostatin LAR increased plasma octreotide levels as determined by radioimmunoassay, but had no significant effect on tumor growth. Western blot analysis revealed an up-regulation of the cyclin-dependent kinase inhibitors p27 and p16 in the SSTR2 transfected tumors.Conclusions.Expression of SSTR2 by human pancreatic cancer causes significant slowing of tumor growth by a mechanism independent of exogenous somatostatin. The mechanism may involve up-regulation of known tumor-suppressor proteins. Restoration of SSTR2 gene expression deserves further study as a potential gene-therapy strategy in human pancreatic cancer. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
30. Molecular Mechanisms in Pathophysiology of Mucopolysaccharidosis and Prospects for Innovative Therapy.
- Author
-
Ago, Yasuhiko, Rintz, Estera, Musini, Krishna Sai, Ma, Zhengyu, and Tomatsu, Shunji
- Subjects
- *
PATHOLOGICAL physiology , *INBORN errors of metabolism , *BIOLOGICAL systems , *MUCOPOLYSACCHARIDOSIS , *GLYCOSAMINOGLYCANS , *MONOCLONAL antibodies , *SKELETAL dysplasia , *LYSOSOMES , *TRANSPOSONS - Abstract
Mucopolysaccharidoses (MPSs) are a group of inborn errors of the metabolism caused by a deficiency in the lysosomal enzymes required to break down molecules called glycosaminoglycans (GAGs). These GAGs accumulate over time in various tissues and disrupt multiple biological systems, including catabolism of other substances, autophagy, and mitochondrial function. These pathological changes ultimately increase oxidative stress and activate innate immunity and inflammation. We have described the pathophysiology of MPS and activated inflammation in this paper, starting with accumulating the primary storage materials, GAGs. At the initial stage of GAG accumulation, affected tissues/cells are reversibly affected but progress irreversibly to: (1) disruption of substrate degradation with pathogenic changes in lysosomal function, (2) cellular dysfunction, secondary/tertiary accumulation (toxins such as GM2 or GM3 ganglioside, etc.), and inflammatory process, and (3) progressive tissue/organ damage and cell death (e.g., skeletal dysplasia, CNS impairment, etc.). For current and future treatment, several potential treatments for MPS that can penetrate the blood–brain barrier and bone have been proposed and/or are in clinical trials, including targeting peptides and molecular Trojan horses such as monoclonal antibodies attached to enzymes via receptor-mediated transport. Gene therapy trials with AAV, ex vivo LV, and Sleeping Beauty transposon system for MPS are proposed and/or underway as innovative therapeutic options. In addition, possible immunomodulatory reagents that can suppress MPS symptoms have been summarized in this review. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes.
- Author
-
di Leandro, Luana, Colasante, Martina, Pitari, Giuseppina, and Ippoliti, Rodolfo
- Subjects
- *
TOXINS , *DIPHTHERIA toxin , *BACTERIAL toxins , *ANTIBODY-toxin conjugates , *EXOTOXIN , *GENE therapy , *MELITTIN , *CHO cell - Abstract
The production of therapeutic recombinant toxins requires careful host cell selection. Bacteria, yeast, and mammalian cells are common choices, but no universal solution exists. Achieving the delicate balance in toxin production is crucial due to potential self-intoxication. Recombinant toxins from various sources find applications in antimicrobials, biotechnology, cancer drugs, and vaccines. "Toxin-based therapy" targets diseased cells using three strategies. Targeted cancer therapy, like antibody–toxin conjugates, fusion toxins, or "suicide gene therapy", can selectively eliminate cancer cells, leaving healthy cells unharmed. Notable toxins from various biological sources may be used as full-length toxins, as plant (saporin) or animal (melittin) toxins, or as isolated domains that are typical of bacterial toxins, including Pseudomonas Exotoxin A (PE) and diphtheria toxin (DT). This paper outlines toxin expression methods and system advantages and disadvantages, emphasizing host cell selection's critical role. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Cationic Materials for Gene Therapy: A Look Back to the Birth and Development of 2,2-Bis-(hydroxymethyl)Propanoic Acid-Based Dendrimer Scaffolds.
- Author
-
Alfei, Silvana
- Subjects
- *
GENE therapy , *DENDRIMERS , *GENE transfection , *HYDROXYMETHYL compounds , *PROPIONIC acid , *DENDRIMERS synthesis , *FUNCTIONAL groups , *BONE regeneration - Abstract
Gene therapy is extensively studied as a realistic and promising therapeutic approach for treating inherited and acquired diseases by repairing defective genes through introducing (transfection) the "healthy" genetic material in the diseased cells. To succeed, the proper DNA or RNA fragments need efficient vectors, and viruses are endowed with excellent transfection efficiency and have been extensively exploited. Due to several drawbacks related to their use, nonviral cationic materials, including lipidic, polymeric, and dendrimer vectors capable of electrostatically interacting with anionic phosphate groups of genetic material, represent appealing alternative options to viral carriers. Particularly, dendrimers are highly branched, nanosized synthetic polymers characterized by a globular structure, low polydispersity index, presence of internal cavities, and a large number of peripheral functional groups exploitable to bind cationic moieties. Dendrimers are successful in several biomedical applications and are currently extensively studied for nonviral gene delivery. Among dendrimers, those derived by 2,2-bis(hydroxymethyl)propanoic acid (b-HMPA), having, unlike PAMAMs, a neutral polyester-based scaffold, could be particularly good-looking due to their degradability in vivo. Here, an overview of gene therapy, its objectives and challenges, and the main cationic materials studied for transporting and delivering genetic materials have been reported. Subsequently, due to their high potential for application in vivo, we have focused on the biodegradable dendrimer scaffolds, telling the history of the birth and development of b-HMPA-derived dendrimers. Finally, thanks to a personal experience in the synthesis of b-HMPA-based dendrimers, our contribution to this field has been described. In particular, we have enriched this work by reporting about the b-HMPA-based derivatives peripherally functionalized with amino acids prepared by us in recent years, thus rendering this paper original and different from the existing reviews. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. The Year in Review: The Top Five Papers of 2018.
- Author
-
Flotte, Terence R.
- Subjects
- *
GENE expression , *GENE therapy , *T cells , *GENETIC engineering , *GENOME editing - Published
- 2018
- Full Text
- View/download PDF
34. The Relevance of Advanced Therapy Medicinal Products in the Field of Transplantation and the Need for Academic Research Access: Overcoming Bottlenecks and Claiming a New Time.
- Author
-
Piemonti, Lorenzo, Scholz, Hanne, de Jongh, Dide, Kerr-Conte, Julie, van Apeldoorn, Aart, Shaw, James A. M., Engelse, Marten A., Bunnik, Eline, Mühlemann, Markus, Pal-Kutas, Karolina, Scott III, William E., Magalon, Jérémy, Kugelmeier, Patrick, and Berishvili, Ekaterine
- Subjects
- *
UNIVERSITY research , *GENE therapy , *TRANSPLANTATION of organs, tissues, etc. , *CELLULAR therapy , *ORGAN donors - Abstract
The field of transplantation has witnessed the emergence of Advanced Therapy Medicinal Products (ATMPs) as highly promising solutions to address the challenges associated with organ and tissue transplantation. ATMPs encompass gene therapy, cell therapy, and tissue-engineered products, hold immense potential for breakthroughs in overcoming the obstacles of rejection and the limited availability of donor organs. However, the development and academic research access to ATMPs face significant bottlenecks that hinder progress. This opinion paper emphasizes the importance of addressing bottlenecks in the development and academic research access to ATMPs by implementing several key strategies. These include the establishment of streamlined regulatory processes, securing increased funding for ATMP research, fostering collaborations and partnerships, setting up centralized ATMP facilities, and actively engaging with patient groups. Advocacy at the policy level is essential to provide support for the development and accessibility of ATMPs, thereby driving advancements in transplantation and enhancing patient outcomes. By adopting these strategies, the field of transplantation can pave the way for the introduction of innovative and efficacious ATMP therapies, while simultaneously fostering a nurturing environment for academic research. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Recent Advances in Mesoporous Silica Nanoparticles Delivering siRNA for Cancer Treatment.
- Author
-
Xie, Xiaowei, Yue, Tianxiang, Gu, Wenting, Cheng, WeiYi, He, Li, Ren, WeiYe, Li, Fanzhu, and Piao, Ji-Gang
- Subjects
- *
MESOPOROUS silica , *SILICA nanoparticles , *SMALL interfering RNA , *CANCER treatment , *GENE silencing - Abstract
Silencing genes using small interfering (si) RNA is a promising strategy for treating cancer. However, the curative effect of siRNA is severely constrained by low serum stability and cell membrane permeability. Therefore, improving the delivery efficiency of siRNA for cancer treatment is a research hotspot. Recently, mesoporous silica nanoparticles (MSNs) have emerged as bright delivery vehicles for nucleic acid drugs. A comprehensive understanding of the design of MSN-based vectors is crucial for the application of siRNA in cancer therapy. We discuss several surface-functionalized MSNs' advancements as effective siRNA delivery vehicles in this paper. The advantages of using MSNs for siRNA loading regarding considerations of different shapes, various options for surface functionalization, and customizable pore sizes are highlighted. We discuss the recent investigations into strategies that efficiently improve cellular uptake, facilitate endosomal escape, and promote cargo dissociation from the MSNs for enhanced intracellular siRNA delivery. Also, particular attention was paid to the exciting progress made by combining RNAi with other therapies to improve cancer therapeutic outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Cell and gene therapy workforce development: the role of the International Society for Cell & Gene Therapy (ISCT) in the creation of a sustainable and skilled workforce in Europe.
- Author
-
Vives, Joaquim, Sánchez-Guijo, Fermín, Gnecchi, Massimiliano, and Zwaginga, Jaap Jan
- Subjects
- *
GENE therapy , *CELLULAR therapy , *LABOR supply , *STEM cell transplantation , *HUMAN origins , *ACTIVE aging - Abstract
The development and production of cell gene and tissue (CGT)-based therapies requires a specialized workforce. Entering the CGT arena is complex because it involves different scientific and biomedical aspects (e.g., immunology, stem cell biology and transplantation), as well as knowledge of regulatory affairs and compliance with pharmaceutical quality standards. Currently, both industry and academia are facing a worldwide workforce shortage, whereas only a handful of educational and training initiatives specifically address the peculiarities of CGT product development, the procurement of substances of human origin, the manufacturing process itself and clinical monitoring and biovigilance. The training offered by traditional Master's and PhD programs is not suited for training a skilled workforce ready to enter the increasingly fast-growing CGT field. Indeed, typically these programs are of long duration and only partially cover the required competencies, whereas the demand for a specialized workforce relentlessly increases. In this paper, we (i) present and discuss our understanding of the roots of current growth acceleration of the CGT field; (ii) anticipate future workforce needs due to the expected increase of marketed CGT-based therapies and (iii) evaluate potential solutions that seek to adapt, develop and implement current educational and training initiatives. Importantly for these solutions, we call for scientific societies, such as the International Society for Cell & Gene Therapy, to play a more active role and act as catalysers for new initiatives, building bridges between academia and Industry to establish effective educational and training programs that will engage and prepare a new generation of qualified professionals for entry into the CGT field. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
37. Reshaping consent so we might improve participant choice (II) – helping people decide.
- Author
-
Davies, Hugh, Munday, Rosie, O'Reilly, Maeve, Gilmour Hamilton, Catriona, Ardahan, Arzhang, Kolstoe, Simon E, and Gillies, Katie
- Subjects
- *
DECISION making , *RESEARCH ethics , *RESEARCH personnel , *ETHICS committees - Abstract
Research consent processes must provide potential participants with the necessary information to help them decide if they wish to join a study. On the Oxford 'A' Research Ethics Committee we've found that current research proposals mostly provide adequate detail (even if not in an easily comprehensible format), but often fail to support decision making, a view supported by published evidence. In a previous paper, we described how consent might be structured, and here we develop the concept of an Information and Decision Aid (IDA) that can support decision making and be used to guide the dialogue between researcher and potential participant. Our proposal requires limited changes to current processes or paperwork and would provide an easily accessible document for others that the potential participant might approach for advice. It could later be integrated with the Informed Consent Form to ensure all matters of concern to the individual participant have been addressed before consent is formally signed off. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches.
- Author
-
Graeber, Simon Y and Mall, Marcus A
- Subjects
- *
BRONCHIECTASIS , *CYSTIC fibrosis , *THERAPEUTICS , *CHRONIC obstructive pulmonary disease , *LUNG diseases , *GENE therapy - Abstract
With the 2019 breakthrough in the development of highly effective modulator therapy providing unprecedented clinical benefits for over 90% of patients with cystic fibrosis who are genetically eligible for treatment, this rare disease has become a front runner of transformative molecular therapy. This success is based on fundamental research, which led to the identification of the disease-causing CFTR gene and our subsequent understanding of the disease mechanisms underlying the pathogenesis of cystic fibrosis, working together with a continuously evolving clinical research and drug development pipeline. In this Series paper, we focus on advances since 2018, and remaining knowledge gaps in our understanding of the molecular mechanisms of CFTR dysfunction in the airway epithelium and their links to mucus dysfunction, impaired host defences, airway infection, and chronic inflammation of the lungs of people with cystic fibrosis. We review progress in (and the remaining obstacles to) pharmacological approaches to rescue CFTR function, and novel strategies for improved symptomatic therapies for cystic fibrosis, including how these might be applicable to common lung diseases, such as bronchiectasis and chronic obstructive pulmonary disease. Finally, we discuss the promise of genetic therapies and gene editing approaches to restore CFTR function in the lungs of all patients with cystic fibrosis independent of their CFTR genotype, and the unprecedented opportunities to transform cystic fibrosis from a fatal disease to a treatable and potentially curable one. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
39. The Relevance of Advanced Therapy Medicinal Products in the Field of Transplantation and the Need for Academic Research Access: Overcoming Bottlenecks and Claiming a New Time.
- Author
-
Piemonti, Lorenzo, Scholz, Hanne, de Jongh, Dide, Kerr-Conte, Julie, Apeldoorn, Aart van, Shaw, James A. M., Engelse, Marten A., Bunnik, Eline, Mühlemann, Markus, Pal-Kutas, Karolina, Scott III, William E., Magalon, Jérémy, Kugelmeier, Patrick, and Berishvili, Ekaterine
- Subjects
- *
UNIVERSITY research , *GENE therapy , *TRANSPLANTATION of organs, tissues, etc. , *CELLULAR therapy , *ORGAN donors - Abstract
The field of transplantation has witnessed the emergence of Advanced Therapy Medicinal Products (ATMPs) as highly promising solutions to address the challenges associated with organ and tissue transplantation. ATMPs encompass gene therapy, cell therapy, and tissueengineered products, hold immense potential for breakthroughs in overcoming the obstacles of rejection and the limited availability of donor organs. However, the development and academic research access to ATMPs face significant bottlenecks that hinder progress. This opinion paper emphasizes the importance of addressing bottlenecks in the development and academic research access to ATMPs by implementing several key strategies. These include the establishment of streamlined regulatory processes, securing increased funding for ATMP research, fostering collaborations and partnerships, setting up centralized ATMP facilities, and actively engaging with patient groups. Advocacy at the policy level is essential to provide support for the development and accessibility of ATMPs, thereby driving advancements in transplantation and enhancing patient outcomes. By adopting these strategies, the field of transplantation can pave the way for the introduction of innovative and efficacious ATMP therapies, while simultaneously fostering a nurturing environment for academic research. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Meeting Contemporary Challenges: Development of Nanomaterials for Veterinary Medicine.
- Author
-
Danchuk, Oleksii, Levchenko, Anna, da Silva Mesquita, Rochelly, Danchuk, Vyacheslav, Cengiz, Seyda, Cengiz, Mehmet, and Grafov, Andriy
- Subjects
- *
VETERINARY medicine , *NANOSTRUCTURED materials , *ANIMAL welfare , *ANIMAL culture , *NANOBIOTECHNOLOGY , *FEED additives , *GENE therapy - Abstract
In recent decades, nanotechnology has been rapidly advancing in various fields of human activity, including veterinary medicine. The review presents up-to-date information on recent advancements in nanotechnology in the field and an overview of the types of nanoparticles used in veterinary medicine and animal husbandry, their characteristics, and their areas of application. Currently, a wide range of nanomaterials has been implemented into veterinary practice, including pharmaceuticals, diagnostic devices, feed additives, and vaccines. The application of nanoformulations gave rise to innovative strategies in the treatment of animal diseases. For example, antibiotics delivered on nanoplatforms demonstrated higher efficacy and lower toxicity and dosage requirements when compared to conventional pharmaceuticals, providing a possibility to solve antibiotic resistance issues. Nanoparticle-based drugs showed promising results in the treatment of animal parasitoses and neoplastic diseases. However, the latter area is currently more developed in human medicine. Owing to the size compatibility, nanomaterials have been applied as gene delivery vectors in veterinary gene therapy. Veterinary medicine is at the forefront of the development of innovative nanovaccines inducing both humoral and cellular immune responses. The paper provides a brief overview of current topics in nanomaterial safety, potential risks associated with the use of nanomaterials, and relevant regulatory aspects. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. Peptide-Based Vectors for Gene Delivery.
- Author
-
Yang, Juan and Luo, Guo-Feng
- Subjects
- *
GENE transfection , *GENE therapy , *GENES , *CELL membranes - Abstract
Gene therapy is the ultimate therapeutic technology for diseases related to gene abnormality. However, the use of DNA alone has serious problems, such as poor stability and difficulty in entering target cells. The development of a safe and efficient gene delivery system is the cornerstone of gene therapy. Of particular interest, multifunctional peptides are rationally designed as non-viral vectors for efficient gene delivery. As components of gene delivery vectors, these peptides play critically important roles in skeleton construction, the implementation of targeting strategies, cell membrane penetration, endosome rupture, and nuclear transport. In recent years, the research of functional peptide-based gene delivery vectors has made important progress in improving transfection efficiency. The latest research progress and future development direction of peptide-based gene delivery vectors are reviewed in this paper. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
42. Artificial Intelligence in Regenerative Medicine: Applications and Implications.
- Author
-
Nosrati, Hamed and Nosrati, Masoud
- Subjects
- *
REGENERATIVE medicine , *ARTIFICIAL intelligence , *TISSUE engineering , *INDIVIDUALIZED medicine , *GENE therapy - Abstract
The field of regenerative medicine is constantly advancing and aims to repair, regenerate, or substitute impaired or unhealthy tissues and organs using cutting-edge approaches such as stem cell-based therapies, gene therapy, and tissue engineering. Nevertheless, incorporating artificial intelligence (AI) technologies has opened new doors for research in this field. AI refers to the ability of machines to perform tasks that typically require human intelligence in ways such as learning the patterns in the data and applying that to the new data without being explicitly programmed. AI has the potential to improve and accelerate various aspects of regenerative medicine research and development, particularly, although not exclusively, when complex patterns are involved. This review paper provides an overview of AI in the context of regenerative medicine, discusses its potential applications with a focus on personalized medicine, and highlights the challenges and opportunities in this field. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
43. Identification of CD73 as a Novel Biomarker Encompassing the Tumor Microenvironment, Prognosis, and Therapeutic Responses in Various Cancers.
- Author
-
Tang, Kun, Zhang, Jingwei, Cao, Hui, Xiao, Gelei, Wang, Zeyu, Zhang, Xun, Zhang, Nan, Wu, Wantao, Zhang, Hao, Wang, Qianrong, Xu, Huilan, and Cheng, Quan
- Subjects
- *
CANCER cell culture , *TISSUE arrays , *FIBROBLASTS , *IMMUNOMODULATORS , *GLIOMAS , *MACROPHAGES , *STROMAL cells , *CANCER , *CELLULAR signal transduction , *GENE therapy , *TUMORS , *TUMOR markers , *T cells , *IMMUNOTHERAPY - Abstract
Simple Summary: Immunotherapy targeting immune checkpoints and stromal cells in the tumor microenvironment is currently one of the most promising directions for tumor therapy. Ongoing studies suggest that CD73 plays an important role in the tumor immune process in certain tumors, however, the exact mechanism is unknown. We aim to fully reveal the prognostic value of CD73 in pan-cancer and its role in tumor immunity through large-scale single-cell and bulk sequencing analysis. We found that high CD73 expression was significantly associated with poor prognosis in many tumors. It is also strongly associated with immune scores, stromal cell infiltration, and immune-related pathways. CD73 can regulate the biological behavior of immune cells in the tumor microenvironment, especially macrophages and T cells. Immunotherapy targeting CD73 has obvious effects, and CD73 may shine as a new immune checkpoint in future tumor immunotherapy. CD73 is essential in promoting tumor growth by prohibiting anti-tumor immunity in many cancer types. While the mechanism remains largely unknown, our paper comprehensively confirmed the onco-immunological characteristics of CD73 in the tumor microenvironment (TME) of pan-cancer. This paper explored the expression pattern, mutational profile, prognostic value, tumor immune infiltration, and response to immunotherapy of CD73 in a continuous cohort of cancers through various computational tools. The co-expression of CD73 on cancer cells, immune cells, and stromal cells in the TME was also detected. Especially, we examined the correlation between CD73 and CD8+ (a marker of T cell), CD68+ (a marker of macrophage), and CD163+ (a marker of M2 macrophage) cells using multiplex immunofluorescence staining of tissue microarrays. CD73 expression is significantly associated with a patient's prognosis and could be a promising predictor of these cancers. High CD73 levels are strongly linked to immune infiltrations, neoantigens, and immune checkpoint expression in the TME. In particular, enrichment signaling pathway analysis demonstrated that CD73 was obviously related to activation pathways of immune cells, including T cells, macrophages, and cancer-associated fibroblasts (CAFs). Meanwhile, single-cell sequencing algorithms found that CD73 is predominantly co-expressed on cancer cells, CAFs, M2 macrophages, and T cells in several cancers. In addition, we explored the cellular communication among 14 cell types in glioblastoma (GBM) based on CD73 expression. Based on the expression of CD73 as well as macrophage and T cell markers, we predicted the methylation and enrichment pathways of these markers in pan-cancer. Furthermore, a lot of therapeutic molecules sensitive to these markers were predicted. Finally, potential anticancer inhibitors, immunotherapies, and gene therapy responses targeting CD73 were identified from a series of immunotherapy cohorts. CD73 is closely linked to clinical prognosis and immune infiltration in many cancers. Targeting CD73-dependent signaling pathways may be a promising therapeutic strategy for future tumor immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
44. Ocular Manifestations and Potential Treatments of Alport Syndrome: A Systematic Review.
- Author
-
Ramakrishnan, Rahul, Shenoy, Atira, and Meyer, Damon
- Subjects
- *
ONLINE information services , *DRUG efficacy , *BLINDNESS , *MEDICAL information storage & retrieval systems , *OCULAR manifestations of general diseases , *NEPHRITIS , *SYSTEMATIC reviews , *SLIT lamp microscopy , *OPERATIVE surgery , *GENETIC disorders , *TREATMENT effectiveness , *GENE therapy , *OPTICAL coherence tomography , *MEDLINE , *RETINAL detachment , *OPHTHALMIC surgery , *PATIENT safety , *EARLY diagnosis - Abstract
Objectives. Alport syndrome (AS) is a severe, rare hereditary disorder that can lead to end-stage renal disease, auditory degeneration, and ocular abnormalities. Despite extensive research on AS in relation to auditory and renal disorders, more research is needed on the ocular presentations of AS. This systematic review aims to summarize the common ocular abnormalities in patients with AS and to explore the potential treatment options for these irregularities. Methods. The PubMed, MEDLINE, and EMBASE databases were systematically searched from January 1977 to April 2022. Only papers that were published in the English language and explored the ocular abnormalities in AS patients were selected. We manually searched reference lists of included papers for additional studies. Results. A total of 23 articles involving 195 patients were included in this review. The common ocular manifestations in AS patients are lenticonus, macular holes, fleck retinopathy, and thinning of the macula. Although published literature has described the use of cataract surgeries and vitrectomies as standard surgical techniques to alleviate ocular abnormalities in non-AS patients, it must be noted that surgical techniques have not been evaluated in a large research study as a solution for AS abnormalities. Another prospective treatment for AS is gene therapy through the reversion of causative COL4 variants to wild type or exon-skipping therapy for X-linked AS with COL4A5 truncating mutations. Gene therapy, however, remains unable to treat alterations that occur in the fetal and early development phase of the disease. Conclusions. The review found no definitive conclusions regarding the efficacy and safety of surgical techniques and gene therapy in AS patients. Recognition of ocular abnormalities through an ophthalmic examination with an optical coherence tomography (OCT) and slit-lamp examination is critical to the medical field, as ophthalmologists can aid nephrologists and other physicians in diagnosing AS. Early diagnosis and care can minimize the risk of detrimental ocular outcomes, such as blindness and retinal detachment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
45. Germline genome editing of human IVF embryos should not be subject to overly stringent restrictions.
- Author
-
Smith, Kevin Richard
- Abstract
This paper critiques the restrictive criteria for germline genome editing recently proposed by Chin, Nguma, and Ahmad in this journal. While praising the authors for resisting fervent calls for an outright ban on clinical applications of the technology, this paper argues that their approach is nevertheless unduly restrictive, and may thus hinder technological progress. This response advocates for weighing potential benefits against risks without succumbing to excessive caution, proposing that ethical oversight combined with genetic scrutiny at the embryo stage post-editing can enable responsible use of the technology, ultimately reducing the burden of genetic diseases and enhancing human health, akin to how IVF transformed reproductive medicine despite strong initial opposition. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Peptide-based non-viral gene delivery: A comprehensive review of the advances and challenges.
- Author
-
Xiang, Kai, Li, Yanan, Cong, Hailin, Yu, Bing, and Shen, Youqing
- Subjects
- *
GENE transfection , *PEPTIDE derivatives , *PEPTIDES , *GENE therapy , *GENETIC vectors , *CELL nuclei , *GENE targeting - Abstract
Gene therapy is the most effective treatment option for diseases, but its effectiveness is affected by the choice and design of gene carriers. The genes themselves have to pass through multiple barriers in order to enter the cell and therefore require additional vectors to carry them inside the cell. In gene therapy, peptides have unique properties and potential as gene carriers, which can effectively deliver genes into specific cells or tissues, protect genes from degradation, improve gene transfection efficiency, and enhance gene targeting and biological responsiveness. This paper reviews the research progress of peptides and their derivatives in the field of gene delivery recently, describes the obstacles encountered by foreign materials to enter the interior of the cell, and introduces the following classes of functional peptides that can carry materials into the interior of the cell, and assist in transmembrane translocation of carriers, thus breaking through endosomal traps to enable successful entry of genetic materials into the nucleus of the cell. The paper also discusses the combined application of peptide vectors with other vectors to enhance its transfection ability, explores current challenges encountered by peptide vectors, and looks forward to future developments in the field. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Non-clinical, quality and environmental impact assessments of cell and gene therapy products: Report on the 5th Asia Partnership Conference of Regenerative Medicine - April 7, 2022.
- Author
-
Tanaka, Toshimitsu, Karasawa, Hiroshi, Yasumoto, Masahiko, Choi, Byung Hyune, Chang, Ryan, Komuro, Masato, Miyano, Masaaki., Moriya, Yuu, Muthusamy, Sasikumar, Okubo, Shingo, Takakura, Koji, Tsurumaki, Yoshie, Watanabe, Takeshi, Wen, Karen, Yoneda, Tomohiro, Yuan, Ta-Tung, and Nomura, Masayuki
- Subjects
- *
ENVIRONMENTAL impact analysis , *ENVIRONMENTAL quality , *GENE therapy , *CELLULAR therapy , *GOVERNMENT agencies - Abstract
The 5th Asia Partnership Conference of Regenerative Medicine (APACRM) was held online on April 7, 2022 to promote regulatory harmonization of regenerative medicine products throughout Asia. The recognition of domestic regulatory guidelines within each country and region and the underpinning rationales are important initial steps toward the harmonization of regulations. The 5th APACRM featured open dialog regarding non-clinical, quality and environmental impact assessment settings for cell and gene therapy products through presentations from the industry and panel discussions with regulatory agencies. The latest updates on regenerative medicine fields in each country and region were also introduced. This paper summarizes the proceedings of the 5th APACRM for public dissemination to foster future discussion. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
48. Trends in prescribing practices for management of haemophilia: 1999–2021.
- Author
-
Curtis, Randall, Roberts, Jonathan C., Crook, Nicole, Decker‐Palmer, Marquita, Khainar, Rahul, Baker, Judith R., Ullman, Megan, Koerper, Marion A., Wu, Joanne, and Nichol, Michael B.
- Subjects
- *
HEMOPHILIA , *HEMOPHILIA treatment , *HEMOPHILIACS , *GENE therapy , *EMICIZUMAB - Abstract
Introduction: People with haemophilia rely on specialists for their care, yet the specific dosing regimens of treatments prescribed by these specialists have not been widely studied. Aim: The objective of this study is to describe trends in clinician prescribing practices for the management of haemophilia in the United States (US). Methods: We administered surveys to members of the Hemostasis and Thrombosis Research Society via paper surveys at its in‐person annual symposia in 1999 and 2015, and an online survey in 2021. The surveys collected information on haemophilia treatments including factor dosing, inhibitor therapy and gene therapy. Results: Clinicians treating haemophilia for more than 50% of their practice time have increased from 37.5% of respondents in 1999 to 46.3% in 2021. Clinicians prescribing factor concentrates at >40 units/kg for routine bleeding events increased from 0% in 1999 to 29.3% in 2021 in haemophilia A (HA) and from 22.5% to 87.8% in haemophilia B (HB). In 2021, the clinicians reported prescribing emicizumab to treat HA patients (>89.5% paediatric, >85.7% adult) with or without inhibitors at least some of the time. Approximately 78.0% of respondents reported that they expected to recommend gene therapy at least some of time. Conclusion: These data indicate changing trends in prescribing practices among US haemophilia specialists during the past 22 years. Preference for high doses of factor (>40 units/kg) has increased during this period. Emicizumab prophylaxis has been prescribed for patients with and without HA inhibitors. Clinicians expect gene therapy to have value for some haemophilia patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
49. CRISPR Gene-Therapy: A Critical Review of Ethical Concerns and a Proposal for Public Decision-Making.
- Author
-
Lange, Victor and Kappel, Klemens
- Subjects
- *
CRISPRS , *GENOME editing , *GENE therapy , *DECISION making , *BIOETHICISTS - Abstract
CRISPR is currently viewed as the central tool for future gene therapy. Yet, many prominent scientists and bioethicists have expressed ethical concerns around CRISPR gene therapy. This paper provides a critical review of concerns about CRISPR gene therapy as expressed in the mainstream academic literature, paired with replies also generally found in that literature. The expressed concerns can be categorised into three types depending on whether they stress risk/benefit ratio, autonomy and informed consent, or concerns related to various aspects of justice. In the reviewed literature, we found no intrinsic objections to CRISPR gene therapy, even though many such objections were present in discussions of gene editing in the 1990s. The paper then proposes a brief outline for a practically applicable moral framework for public decision-making about CRISPR gene therapy and suggests how such a framework might be supported. We also suggest that this framework should govern public engagement about CRISPR gene therapy in order to reduce the risk that we make decisions about CRISPR gene therapy based on misperceptions, inflated views of risk, or unreasonable moral or religious views. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
50. Huntington's Disease: Mechanisms of pathogenesis and therapies.
- Author
-
Zheng, Qianqian, Li, Lina, and Yang, Lingyan
- Subjects
- *
HUNTINGTON disease , *MOVEMENT disorders , *GENE therapy , *PATHOGENESIS , *PERSONALITY change , *DYSPLASIA - Abstract
Huntington's Disease (HD) is a rare autosomal dominant neurodegenerative disorder. Typical symptoms of HD include personality changes, depression, and chorea. It is cause by elongated CAG repeats in the Huntingtin gene, or HTT gene. The when there are more than 40 repeats of CAG in the mutated HTT gene (mhtt), HD will be expressed in adulthood. And the early onset (teenage) of HD usually occurs when more than 60 repeats exist. Expressing mhtt gene will cause death of medium spiny neurons (MSN) and results in movement disorders or chorea in HD patients. Noticeably, 95% of the neuron population is made of MSN, which is vulnerable to glutamatergic toxicity (excitotoxicity) and studies suggests that excitotoxicity neuron death is associated with neurodegeneration in HD. There is currently no cure to HD, but several gene therapies, including Antisense oligonucleotides (ASOs) and RNAi therapy with Adeno-associated viral (AAV) can effectively delay or control the disease progression. This paper briefly introduces HD's pathogenesis and two gene therapies to treat it, and hope to provide clear clues for future studies that focuses on gene therapies of HD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.